

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Ophthalmic disease</b>				
Glaucoma	Caveolin 1 caveolae protein 22kDa (CAV1); caveolin 2 (CAV2)	Genomewide association studies identified a SNP that could help predict risk of primary open-angle glaucoma. In a genetic analysis, primary open-angle patients of Icelandic descent had greater occurrence of a common sequence variant, rs4236601, near <i>CAV1</i> and <i>CAV2</i> than healthy controls ( $p=5 \times 10^{-10}$ ). The variant also was significantly associated with the disease in both a Chinese and a Swedish, U.K. and Australian replication cohort. Future work could include integrating the SNP into a genetic test for glaucoma.	Patent application filed covering use in glaucoma; available for licensing <b>Contact:</b> Jakob Sigurdsson, deCode genetics Inc., Reykjavik, Iceland e-mail: <a href="mailto:bd@decode.is">bd@decode.is</a>	Thorleifsson, G. <i>et al. Nat. Genet.</i> ; published online Sept. 12, 2010; doi:10.1038/ng.661 <b>Contact:</b> Gudmar Thorleifsson, deCode genetics Inc., Reykjavik, Iceland e-mail: <a href="mailto:gudmar.thorleifsson@decode.is">gudmar.thorleifsson@decode.is</a>
<p><b>SciBX 3(37); doi:10.1038/scibx.2010.1128</b>  <b>Published online Sept. 23, 2010</b></p>				